To achieve secure communication in heterogeneous cryptography systems, we present a heterogeneous hybrid signcryption scheme. The proposed scheme allows a sender in an identity-based cryptography system to send multi-message to multi-receiver in a certificateless cryptography system with different master keys. At the same time, all users are mapped to a distinct pseudo-identity for conditional identity privacy preservation. A trusted authority could trace the real identity when necessary. Compared with existing schemes, the proposed scheme is more practical for actual applications. In addition, the proposed scheme has indistinguishability against adaptive chosen ciphertext attacks and existential unforgeability against adaptive chosen message attacks under the random oracle model.

Tremendous efforts have been devoted to the enhancement of drug solubility using nanotechnologies, but few of them are capable to produce drug particles with sizes less than a few nanometers. This challenge has been addressed here by using biocompatible versatile γ-cyclodextrin (γ-CD) metal-organic framework (CD-MOF) large molecular cages in which azilsartan (AZL) was successfully confined producing clusters in the nanometer range. This strategy allowed to improve the bioavailability of AZL in Sprague–Dawley rats by 9.7-fold after loading into CD-MOF. The apparent solubility of AZL/CD-MOF was enhanced by 340-fold when compared to the pure drug. Based on molecular modeling, a dual molecular mechanism of nanoclusterization and complexation of AZL inside the CD-MOF cages was proposed, which was confirmed by small angle X-ray scattering (SAXS) and synchrotron radiation-Fourier transform infrared spectroscopy (SR-FTIR) techniques. In a typical cage-like unit of CD-MOF, three molecules of AZL were included by the γ-CD pairs, whilst other three AZL molecules formed a nanocluster inside the 1.7 nm sized cavity surrounded by six γ-CDs. This research demonstrates a dual molecular mechanism of complexation and nanoclusterization in CD-MOF leading to significant improvement in the bioavailability of insoluble drugs.

No abstract